Editorial: Chrononutrition and MASLD—It is About Time (Restricted Feeding)! Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

We sincerely appreciate the opportunity to respond editorial by Mohr and Stine discussing our study on effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [1, 2]. are grateful for their insightful commentary highlighting strengths randomised controlled trial (RCT). Their analysis underscores emerging role chrononutrition managing MASLD while also key questions regarding independent contribution TRF caloric restriction improvements. There is indeed great need studies that directly compare ad libitum protocols evaluate differentiative impact several parameters. Most have compared either usual dietary habits participants or hypocaloric diets both control groups, as study. Our was first RCT used Mediterranean Diet (MD) group, gold standard [3]. The MD has been extensively documented an effective intervention [4]. adds this body evidence demonstrating MD, even over short-term period, yields significant improvements weight, fat, blood pressure fat content [1]. Regarding comment generalizability results [2], it true Greece country, described previous studies, Greeks' adherence moderate [5]. [1] agree these [5] may enhanced participants' adherence. interventions (early late) did not seem improve parameters mentioned above further population However, insulin resistance haemoglobin A1c (HbA1c) were only improved early but late group. reduction HbA1c group (0.3% total, 0.37% those T2DM under TRF) greater than other similar example, 0.2% Wei et al. + group) [6], whilst grade improvement associated lower mortality individuals [7] diabetic complications [8]. Prior suggest aligning food intake circadian rhythms light/dark cycle via enhance glucose metabolism humans diurnal [9]. This particularly relevant patients, where pivotal driver progression [10]. That means differences observed probably due intervention, all groups had same restriction. would like thank authors thoughtful comments, which allowed us refine interpretation highlight robustness findings. Future research will provide answers raised concerns. Sofia Tsitsou: writing – original draft, investigation, methodology, data curation. Magdalini Adamantou: curation, investigation. Triada Bali: Aristi Saridaki: Kalliopi-Anna Poulia: methodology. Dimitrios S. Karagiannakis: Emilia Papakonstantinou: Evangelos Cholongitas: conceptualization, review editing, project administration, supervision, visualization, draft. declare no conflicts interest. article linked Tsitsou al papers. To view articles, visit https://doi.org/10.1111/apt.70044 https://doi.org/10.1111/apt.70078. support findings available request from corresponding author. publicly privacy ethical restrictions.

Language: Английский

---

MetALD: New Perspectives on an Old Overlooked Disease

Liver International, Journal Year: 2025, Volume and Issue: 45(5)

Published: April 3, 2025

ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.

Language: Английский

---

Identification of pediatric MASLD using insulin resistance indices

JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101419 - 101419

Published: April 1, 2025

Language: Английский

---

Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults

Internal and Emergency Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Language: Английский

---

Metabolic Characteristics and Cytokine Gene Polymorphisms as Potential Risk Factors for a Higher Liver Fibrosis Stage in MASLD Patients: A Hospital-Based Study

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3730 - 3730

Published: April 15, 2025

Polymorphisms in the Toll-like receptor 4 (TLR4) and IL-17 cytokine genes play a role liver fibrosis progression among patients with MASLD. The current study aimed to investigate whether IL17 (A7448G G197A) TLR4 (Asp299Gly Thr399Ile) gene polymorphisms are associated increased stages MASLD patients. Genotyping for IL17F-A7488G, IL17A-G197A, TLR4-Asp299Gly, TLR4-Thr399Ile was performed on sample of 42 39 healthy controls. Serum levels IL17F, IL17A, were measured using ELISA techniques. Bivariate analysis revealed significant associations between glycemic (p = 0.006), lipid metabolism (total cholesterol, HDL triglycerides), severity < 0.05). IL17A-G197A GA AA genotypes more frequent advanced compared those without (GA genotype frequency: 42.9% vs. 7.7%; 14.3% 5.1%; adjusted p 0.0423). In multivariable ordinal logistic regression, polymorphism remained significantly higher (adjusted 0.0155). Patients dominant + AA) exhibited 3.91 times greater odds experiencing at least one-stage increase GG OR 3.91, 95% CI: 1.33–12.34). This indicates that IL17-related genetic metabolic characteristics affect patients, identified as an independent multivariate predictor progression.

Language: Английский

---

Exploring the association between dietary indices and metabolic dysfunction-associated steatotic liver disease: Mediation analysis and evidence from NHANES

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0321251 - e0321251

Published: April 17, 2025

Background The association between dietary indices and metabolic dysfunction-associated steatotic liver disease (MASLD) has shown inconsistent results in previous studies. Additionally, the potential mediating variables linking quality to MASLD have not been adequately explored. Methods We analyzed data from 6,369 participants National Health Nutrition Examination Survey (NHANES) 2007–2018. Three indices—Healthy Eating Index (HEI), Energy-adjusted Dietary Inflammatory (EDII), Composite Antioxidant (CDAI)—were evaluated for their associations with using logistic regression models adjusted a comprehensive range of covariates. Mediation analysis was performed evaluate roles mediators four domains: insulin resistance (homeostatic model assessment resistance, HOMA-IR; score METS-IR), systemic inflammation (systemic inflammatory response index, SIRI; immune-inflammation SII), obesity or visceral fat distribution (a body shape ABSI; roundness BRI), oxidative stress (Gamma-Glutamyltransferase, GGT; Bilirubin; Uric Acid). Results After adjusting all covariates, only HEI showed consistent inverse MASLD, while EDII CDAI no significant associations. identified METS-IR, HOMA-IR, BRI, ABSI as relationship mediation proportion accounting 47.16%, 48.84%, 52.69%, 13.84%, respectively. Conclusion Higher is associated reduced risk MASLD. findings suggest that partially mediate providing insights into mechanisms diet health.

Language: Английский

---

Targeting Metabolism: Innovative Therapies for MASLD Unveiled

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4077 - 4077

Published: April 25, 2025

The recent introduction of the term metabolic-dysfunction-associated steatotic liver disease (MASLD) has highlighted critical role metabolism in disease’s pathophysiology. This innovative nomenclature signifies a shift from previous designation non-alcoholic fatty (NAFLD), emphasizing condition’s progressive nature. Simultaneously, MASLD become one most prevalent diseases worldwide, highlighting urgent need for research to elucidate its etiology and develop effective treatment strategies. review examines delineates revised definition MASLD, exploring epidemiology pathological changes occurring at various stages disease. Additionally, it identifies metabolically relevant targets within provides summary latest targeted drugs under development, including those clinical some preclinical stages. finishes with look ahead future therapy goal summarizing providing fresh ideas insights.

Language: Английский

---

Weissella viridescens Attenuates Hepatic Injury, Oxidative Stress, and Inflammation in a Rat Model of High-Fat Diet-Induced MASLD

Nutrients, Journal Year: 2025, Volume and Issue: 17(9), P. 1585 - 1585

Published: May 5, 2025

Background/Objectives: Metabolic-dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic disorder globally. Probiotic supplementation has shown promise in its prevention and treatment. Although Weissella viridescens, a lactic acid bacterium with immunomodulatory effects, antibacterial anti-inflammatory activities, there lack of direct evidence for role MASLD. This study aimed to investigate protective effects W. viridescens strain Wv2365, isolated from healthy human feces, high-fat diet (HFD)-induced rat model Methods: Rats were randomly assigned normal chow (NC), (HFD), HFD supplemented Wv2365 (Wv2365) groups. All groups fed their respective diets 8 weeks. During this period, NC received daily oral gavage PBS, while group Wv2365. Results: significantly reduced HFD-induced body weight gain, improved NAFLD activity scores, alleviated hepatic injury, restored lipid metabolism. A transcriptomic analysis revealed downregulation inflammation-related pathways, along decreased serum levels TNF-α, IL-1β, IL-6, MCP-1, LPS. also activated Nrf2/HO-1 antioxidant pathway, enhancing enzyme activities reducing malondialdehyde (MDA) levels. gut microbiota showed enrichment beneficial genera, including Butyricicoccus, Akkermansia, Blautia. Serum metabolomic profiling increased metabolites indole-3-propionic (IPA), indoleacrylic (IA), glycolithocholic (GLCA). Conclusions: attenuates oxidative stress, inflammation high-fat-diet-induced MASLD, supporting potential as probiotic candidate modulation

Language: Английский

---

Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies

Food and Agricultural Immunology, Journal Year: 2025, Volume and Issue: 36(1)

Published: May 6, 2025

Language: Английский

---

The impact of leptin receptor (LepR) mutation on the development of MASLD in a murine model

Gene, Journal Year: 2025, Volume and Issue: unknown, P. 149550 - 149550

Published: May 1, 2025

Language: Английский

---